We are live on ! Find out more
SHAC

SCP & CO Healthcare Acquisition Company Class A Common Stock

Delisted

SHAC was delisted on the 9th of December, 2022.

0 hedge funds and large institutions have $0 invested in SCP & CO Healthcare Acquisition Company Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 67 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 680 (-68)

100% less capital invested

Capital invested by funds: $212M → $0 (-$212M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 67

Holders
Holders Change
-68
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
67
Calls
Puts
Net Calls
Net Calls Change

SHAC Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in SCP & CO Healthcare Acquisition Company Class A Common Stock (SHAC) for Q4 2022, worth a combined $0 — down 100% from $212M a quarter earlier.

Sellers outnumbered buyers: 67 funds closed out of SHAC and 0 opened new positions — a net loss of 67 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Balyasny Asset Management, exiting entirely with an estimated $17.1M sold.

  • 0 institutional investors held SCP & CO Healthcare Acquisition Company Class A Common Stock (SHAC) as of Q4 2022, down from 68 in Q3 2022.
  • Funds reported $0 of SCP & CO Healthcare Acquisition Company Class A Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new SCP & CO Healthcare Acquisition Company Class A Common Stock positions in Q4 2022 and 67 closed out, a net change of -67 holders.
  • The largest SCP & CO Healthcare Acquisition Company Class A Common Stock seller in Q4 2022 was Balyasny Asset Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q4 2022.